The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Psoriasis pathogenesis and the development of novel targeted immune therapies
Open accessAbstract
&NA; Psoriasis is caused by a complex interplay between the immune system, psoriasis‐associated susceptibility loci, autoantigens, and multiple environmental factors. Over the last 2 decades, research has unequivocally shown that psoriasis represents a bona fide T cell–mediated disease primarily driven by pathogenic T cells that produce high levels of IL‐17 in response to IL‐23. The discovery of the central role for the IL‐23/type 17 T‐cell axis in the development of psoriasis has led to a major paradigm shift in the pathogenic model for this condition. The activation and upregulation of IL‐17 in prepsoriatic skin produces a “feed forward” inflammatory response in keratinocytes that is self‐amplifying and drives the development of mature psoriatic plaques by inducing epidermal hyperplasia, epidermal cell proliferation, and recruitment of leukocyte subsets into the skin. Clinical trial data for mAbs against IL‐17 signaling (secukinumab, ixekizumab, and brodalumab) and newer IL‐23p19 antagonists (tildrakizumab, guselkumab, and risankizumab) underscore the central role of these cytokines as predominant drivers of psoriatic disease. Currently, we are witnessing a translational revolution in the treatment and management of psoriasis. Emerging bispecific antibodies offer the potential for even better disease control, whereas small‐molecule drugs offer future alternatives to the use of biologics and less costly long‐term disease management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antimicrobial peptides of multicellular organisms
Zasloff, M. (2002) · Nature · doi:10.1038/415389a · Cited by 8,457
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
Nestle, F. O., Kaplan, D. H., & Barker, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804595 · Cited by 2,786
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.-H., Homey, B., Cao, W., Wang, Y.-H., Su, B., Nestle, F. O., et al. (2007) · Nature · doi:10.1038/nature06116 · Cited by 1,910
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. (2007) · Nature · doi:10.1038/nature05505 · Cited by 1,862
Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120225 · Cited by 1,650
Self-citationPsoriasis causes as much disability as other major medical diseases
Rapp, S. R., Feldman, S. R., Exum, M. L., Fleischer, A. B., & Reboussin, D. M. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70112-x · Cited by 1,491
Generation of pathogenic TH17 cells in the absence of TGF-β signalling
Ghoreschi, K., Laurence, A., Yang, X.-P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L., Wei, L., Davidson, T. S., Bouladoux, N., et al. (2010) · Nature · doi:10.1038/nature09447 · Cited by 1,388
Psoriasis and comorbid diseases
Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N., Ogdie, A., Van Voorhees, A. S., & Gelfand, J. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.07.064 · Cited by 1,145
Plasmacytoid predendritic cells initiate psoriasis through interferon-α production
Nestle, F. O., Conrad, C., Tun-Kyi, A., Homey, B., Gombert, M., Boyman, O., Burg, G., Liu, Y.-J., & Gilliet, M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050500 · Cited by 1,124
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056 · cited 2×
“The association of IL-17 blockade with Candida infections likely reflects the normal role for this cytokine in the innate immune response against this organism; therefore its absence renders the skin susceptible to overgrowth in the skin and mucosal tissues, as observed in patients with inborn errors in IL-17.(72) Les…”
Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling
Eyerich, S., Eyerich, K., Pennino, D., Carbone, T., Nasorri, F., Pallotta, S., Cianfarani, F., Odorisio, T., Traidl-Hoffmann, C., Behrendt, H., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci40202 · Cited by 1,052
Blauvelt, A., Papp, K. A., Griffiths, C. E. M., Randazzo, B., Wasfi, Y., Shen, Y.-K., Li, S., & Kimball, A. B. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.11.041 · Cited by 897
McInnes, I. B., Mease, P. J., Kirkham, B., Kavanaugh, A., Ritchlin, C. T., Rahman, P., van der Heijde, D., Landewé, R., Conaghan, P. G., Gottlieb, A. B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61134-5 · Cited by 858
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Gordon, K. B., Blauvelt, A., Papp, K. A., Langley, R. G., Luger, T., Ohtsuki, M., Reich, K., Amato, D., Ball, S. G., Braun, D. K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512711 · Cited by 848
Griffiths, C. E. M., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., Cameron, G. S., Erickson, J., Zhang, L., Secrest, R. J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60125-8 · Cited by 834
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503824 · Cited by 828
Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation
Gagliani, N., Vesely, M. C. A., Iseppon, A., Brockmann, L., Xu, H., Palm, N. W., de Zoete, M. R., Licona-Limón, P., Paiva, R. S., Ching, T., et al. (2015) · Nature · doi:10.1038/nature14452 · Cited by 802
Psoriasis prevalence among adults in the United States
Rachakonda, T. D., Schupp, C. W., & Armstrong, A. W. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.11.013 · Cited by 783
Reich, K., Armstrong, A. W., Foley, P., Song, M., Wasfi, Y., Randazzo, B., Li, S., Shen, Y.-K., & Gordon, K. B. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.11.042 · Cited by 761
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Mease, P. J., McInnes, I. B., Kirkham, B., Kavanaugh, A., Rahman, P., van der Heijde, D., Landewé, R., Nash, P., Pricop, L., Yuan, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412679 · Cited by 746
Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8
Ganguly, D., Chamilos, G., Lande, R., Gregorio, J., Meller, S., Facchinetti, V., Homey, B., Barrat, F. J., Zal, T., & Gilliet, M. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090480 · Cited by 740
Chiricozzi, A., Guttman-Yassky, E., Suárez-Fariñas, M., Nograles, K. E., Tian, S., Cardinale, I., Chimenti, S., & Krueger, J. G. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.340 · Cited by 686
Self-citationGottlieb, S. L., Gilleaudeau, P., Johnson, R., Estes, L., Woodworth, T. G., Gottlieb, A. B., & Krueger, J. G. (1995) · Nature Medicine · doi:10.1038/nm0595-442 · Cited by 606
Self-citationCTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Goldfarb, M. T., Goffe, B. S., Menter, A., Lowe, N. J., Krueger, G., Brown, M. J., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5857 · Cited by 597
Self-citationMease, P. J., van der Heijde, D., Ritchlin, C. T., Okada, M., Cuchacovich, R. S., Shuler, C. L., Lin, C.-Y., Braun, D. K., Lee, C. H., & Gladman, D. D. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209709 · Cited by 580
A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis
Lebwohl, M., Tyring, S. K., Hamilton, T. K., Toth, D., Glazer, S., Tawfik, N. H., Walicke, P., Dummer, W., Wang, X., Garovoy, M. R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030002 · Cited by 570
Teunissen, M. B. M., Bos, J. D., Koomen, C. W., de Waal Malefyt, R., & Wierenga, E. A. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00347.x · Cited by 570
Cyclosporine Improves Psoriasis in a Double-blind Study
Ellis, C. N. (1986) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1986.03380220076026 · Cited by 558
Thaçi, D., Blauvelt, A., Reich, K., Tsai, T.-F., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Hugot, S., You, R., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.013 · Cited by 551
The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis
Lande, R., Botti, E., Jandus, C., Dojcinovic, D., Fanelli, G., Conrad, C., Chamilos, G., Feldmeyer, L., Marinari, B., Chon, S., et al. (2014) · Nature Communications · doi:10.1038/ncomms6621 · Cited by 539
The Risk of Mortality in Patients With Psoriasis: Results From a Population-Based Study
Gelfand, J. M., Troxel, A. B., Lewis, J. D., Kurd, S. K., Shin, D. B., Wang, X., Margolis, D. J., & Strom, B. L. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.12.1493 · Cited by 533
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Papp, K. A., Blauvelt, A., Bukhalo, M., Gooderham, M., Krueger, J. G., Lacour, J.-P., Menter, A., Philipp, S., Sofen, H., Tyring, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607017 · Cited by 514
Self-citationHarper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., & Blauvelt, A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.65 · Cited by 508
Apte, S. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.052340 · Cited by 506
Paul, C., Cather, J., Gooderham, M., Poulin, Y., Mrowietz, U., Ferrandiz, C., Crowley, J., Hu, C., Stevens, R. M., Shah, K., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14164 · Cited by 484
Papp, K. A., Reich, K., Paul, C., Blauvelt, A., Baran, W., Bolduc, C., Toth, D., Langley, R. G., Cather, J., Gottlieb, A. B., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14493 · Cited by 470
Self-citationLowes, M. A., Chamian, F., Abello, M. V., Fuentes-Duculan, J., Lin, S.-L., Nussbaum, R., Novitskaya, I., Carbonaro, H., Cardinale, I., Kikuchi, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509736102 · Cited by 456
Self-citationThe Role of Cathelicidins in the Innate Host Defenses of Mammals
(2005) · Current Issues in Molecular Biology · doi:10.21775/cimb.007.179 · Cited by 393
Tsoi, L. C., Stuart, P. E., Tian, C., Gudjonsson, J. E., Das, S., Zawistowski, M., Ellinghaus, E., Barker, J. N., Chandran, V., Dand, N., et al. (2017) · Nature Communications · doi:10.1038/ncomms15382 · Cited by 384
Angiogenesis drives psoriasis pathogenesis
Heidenreich, R., Röcken, M., & Ghoreschi, K. (2009) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2009.00669.x · Cited by 383
Melanocyte antigen triggers autoimmunity in human psoriasis
Arakawa, A., Siewert, K., Stöhr, J., Besgen, P., Kim, S.-M., Rühl, G., Nickel, J., Vollmer, S., Thomas, P., Krebs, S., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20151093 · Cited by 361
Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin
Johansen, C., Usher, P. A., Kjellerup, R. B., Lundsgaard, D., Iversen, L., & Kragballe, K. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08902.x · Cited by 352
Langley, R. G., Tsai, T. ‐., Flavin, S., Song, M., Randazzo, B., Wasfi, Y., Jiang, J., Li, S., & Puig, L. (2018) · British Journal of Dermatology · doi:10.1111/bjd.15750 · Cited by 341
The Immunopathogenesis of Psoriasis
Kim, J., & Krueger, J. G. (2015) · Dermatologic Clinics · doi:10.1016/j.det.2014.09.002 · Cited by 331
Self-citationRes, P. C. M., Piskin, G., de Boer, O. J., van der Loos, C. M., Teeling, P., Bos, J. D., & Teunissen, M. B. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014108 · Cited by 328
Sofen, H., Smith, S., Matheson, R. T., Leonardi, C. L., Calderon, C., Brodmerkel, C., Li, K., Campbell, K., Marciniak, S. J., Wasfi, Y., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.01.025 · Cited by 320
Self-citationResident and “Inflammatory” Dendritic Cells in Human Skin
Zaba, L. C., Krueger, J. G., & Lowes, M. A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.225 · Cited by 319
Self-citationBlauvelt, A., Reich, K., Tsai, T.-F., Tyring, S., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Vender, R., Hugot, S., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.08.008 · Cited by 312
TIILIKAINEN, A., LASSUS, A., KARVONEN, J., VARTIAINEN, P., & JULIN, M. (1980) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1980.tb05690.x · Cited by 303
Effector and Regulatory T-cell Subsets in Autoimmunity and Tissue Inflammation
Jäger, A., & Kuchroo, V. K. (2010) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2010.02432.x · Cited by 282
Economic Burden of Psoriasis in the United States: A Systematic Review
Brezinski, E. A., Dhillon, J. S., & Armstrong, A. W. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2014.3593 · Cited by 261
Krueger, J. G., Ferris, L. K., Menter, A., Wagner, F., White, A., Visvanathan, S., Lalovic, B., Aslanyan, S., Wang, E. E. L., Hall, D., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.01.018 · Cited by 256
Self-citationCheung, K. L., Jarrett, R., Subramaniam, S., Salimi, M., Gutowska-Owsiak, D., Chen, Y.-L., Hardman, C., Xue, L., Cerundolo, V., & Ogg, G. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160258 · Cited by 249
Immunocompetent cells in psoriasis: In situ immunophenotyping by monoclonal antibodies
Bos, J. D., Hulsebosch, H. J., Krieg, S. R., Bakker, P. M., & Cormane, R. H. (1983) · Archives of Dermatological Research · doi:10.1007/bf00510050 · Cited by 236
Chang, J. C., Smith, L. R., Froning, K. J., Schwabe, B. J., Laxer, J. A., Caralli, L. L., Kurland, H. H., Karasek, M. A., Wilkinson, D. I., & Carlo, D. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9282 · Cited by 232
Wang, C. Q. F., Akalu, Y. T., Suarez-Farinas, M., Gonzalez, J., Mitsui, H., Lowes, M. A., Orlow, S. J., Manga, P., & Krueger, J. G. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.237 · Cited by 232
Self-citationPsoriasis and comorbid diseases
Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N., Ogdie, A., Van Voorhees, A. S., & Gelfand, J. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.07.065 · Cited by 226
Bos, J. D., Hagenaars, C., Das, P. K., Krieg, S. R., Voorn, W. J., & Kapsenberg, M. L. (1989) · Archives of Dermatological Research · doi:10.1007/bf00424268 · Cited by 221
Quaranta, M., Knapp, B., Garzorz, N., Mattii, M., Pullabhatla, V., Pennino, D., Andres, C., Traidl-Hoffmann, C., Cavani, A., Theis, F. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008946 · Cited by 209
Brandrup, F., Holm, N. V., Grunnet, N., et al. (1982) · Acta Dermato Venereologica · doi:10.2340/0001555562229236 · Cited by 198
Clearance of severe psoriasis after allogenic bone marrow transplantation.
Eedy, D. J., Burrows, D., Bridges, J. M., & Jones, F. G. (1990) · BMJ · doi:10.1136/bmj.300.6729.908 · Cited by 178
Interleukin-17 in inflammatory skin disorders
van Beelen, A. J., Teunissen, M. B., Kapsenberg, M. L., & de Jong, E. C. (2007) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0b013e3282ef869e · Cited by 175
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis
Kim, J., & Krueger, J. G. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103905 · Cited by 174
Self-citationvan Baarsen, L. G. M., Lebre, M. C., van der Coelen, D., Aarrass, S., Tang, M. W., Ramwadhdoebé, T. H., Gerlag, D. M., & Tak, P. P. (2014) · Arthritis Research & Therapy · doi:10.1186/s13075-014-0426-z · Cited by 164
Cho, K., Suh, J. W., Lee, K. H., Kang, J. L., & Woo, S. (2011) · International Immunology · doi:10.1093/intimm/dxr110 · Cited by 161
Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self‐DNA
Lande, R., Chamilos, G., Ganguly, D., Demaria, O., Frasca, L., Durr, S., Conrad, C., Schröder, J., & Gilliet, M. F. (2014) · European Journal of Immunology · doi:10.1002/eji.201344277 · Cited by 157
IL-29 Is Produced by T H 17 Cells and Mediates the Cutaneous Antiviral Competence in Psoriasis
Wolk, K., Witte, K., Witte, E., Raftery, M., Kokolakis, G., Philipp, S., Schönrich, G., Warszawska, K., Kirsch, S., Prösch, S., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006245 · Cited by 136
Fuentes‐Duculan, J., Bonifacio, K. M., Hawkes, J. E., Kunjravia, N., Cueto, I., Li, X., Gonzalez, J., Garcet, S., & Krueger, J. G. (2017) · Experimental Dermatology · doi:10.1111/exd.13378 · Cited by 129
Self-citationDevelopment and use of alefacept to treat psoriasis
Krueger, G. G., & Callis, K. P. (2003) · Journal of the American Academy of Dermatology · doi:10.1016/mjd.2003.552 · Cited by 106
Li, J., Gran, B., Zhang, G., Ventura, E. S., Siglienti, I., Rostami, A. M., & Kamoun, M. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(03)00203-x · Cited by 105
Victor, E. S., Fickenscher, H., & Bayry, J. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005624 · Cited by 79
Chiba, H., Michibata, H., Wakimoto, K., Seishima, M., Kawasaki, S., Okubo, K., Mitsui, H., Torii, H., & Imai, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305801200 · Cited by 78
Bader, H. L., Wang, L. W., Ho, J., Trần, T. H., Holden, P. K., Fitzgerald, J., Atit, R. P., Reinhardt, D. P., & Apte, S. (2012) · Matrix Biology · doi:10.1016/j.matbio.2012.09.003 · Cited by 66
A revolutionary therapeutic approach for psoriasis: bispecific biological agents
Torres, T., Romanelli, M., & Chiricozzi, A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1187130 · Cited by 54
Harden, J. L., Hamm, D. E., Gulati, N., Lowes, M. A., & Krueger, J. G. (2015) · F1000Research · doi:10.12688/f1000research.6756.1 · Cited by 48
Self-citationHaider, A. S., Cohen, J., Ji, F., Zaba, L. C., Cardinale, I. R., Kikuchi, T., Ott, J., & Krueger, J. G. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701064 · Cited by 40
Self-citationRORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease
de Wit, J., Al‐Mossawi, H., Hühn, M. H., Arancibia-Cárcamo, C. V., Doig, K., Kendrick, B. J. L., Gundle, R., Taylor, P. C., McClanahan, T., Murphy, E., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.09.048 · Cited by 37
Cited by
Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. W. N. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32549-6 · Cited by 2,383
Advances in the pathogenesis of psoriasis: from keratinocyte perspective
Zhou, X., Chen, Y., Cui, L., Shi, Y., & Guo, C. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04523-3 · Cited by 632
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
Hawkes, J. E., Yan, B. Y., Chan, T. C., & Krueger, J. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800013 · Cited by 593
Self-citationThe IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
Brembilla, N. C., Senra, L., & Boehncke, W.-H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01682 · Cited by 475
The IL-17 family in diseases: from bench to bedside
Huangfu, L., Li, R., Huang, Y., & Wang, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01620-3 · Cited by 452
Metadata
- Authors
- Hawkes, J. E., Chan, T. C., & Krueger, J. G.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 140
- Issue
- 3
- Pages
- 645-653
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2752721387
- Cited by
- 972
- References
- 79
- FWCI
- 30.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.